Renhong Tang
YOU?
Author Swipe
View article: A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes
A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes Open
FGFR2b expression may serve as a predictive biomarker for therapeutic response of FGFR2b-targeted agents in sqNSCLC. The high co-expression rate of FGFR2b and PD-L1 supports the feasibility of combining FGFR2b-targeted agents with immune c…
View article: ZMS-6659, a selective Polθ helicase inhibitor, demonstrates anti-tumor activity as monotherapy and synergy effect with PARP inhibitors and topoisomerase inhibitors
ZMS-6659, a selective Polθ helicase inhibitor, demonstrates anti-tumor activity as monotherapy and synergy effect with PARP inhibitors and topoisomerase inhibitors Open
The repair of DNA double strand break (DSB) is crucial for genome stability. Homologous recombination (HR) is a high-fidelity, error-free DSB repair pathway, and its dysfunction leads to genome instability and can result in tumorigenesis. …
View article: Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China
Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China Open
In real world, S/R significantly reduced the incidence of COVID-19-related hospitalization, demonstrated favorable safety profiles, and less use of combined medication.
View article: SCR‐7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the <i>S</i>‐adenosylmethionine‐competitive or the methylthioadenosine‐cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase‐deleted tumors
SCR‐7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the <i>S</i>‐adenosylmethionine‐competitive or the methylthioadenosine‐cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase‐deleted tumors Open
The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was found to elicit synthetic lethality in methylthioadenosine phosphorylase ( MTAP )‐deleted cancers, which occur in about 15% of all cancers. Here, we described a novel MAT2A…
View article: 21 A first-in-human phase 1 study of SIM0417, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects
21 A first-in-human phase 1 study of SIM0417, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects Open
Introduction Safe and efficacious antiviral therapeutics are in urgent need for treatment of coronavirus disease 2019. SIM0417 is a selective 3C-like protease inhibitor that can effectively inhibit severe acute respiratory syndrome coronav…
View article: Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke
Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke Open
Importance Sublingual edaravone dexborneol, which can rapidly diffuse and be absorbed through the oral mucosa after sublingual exposure, is a multitarget brain cytoprotection composed of antioxidant and anti-inflammatory ingredients edarav…
View article: Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 Open
Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19, without evident safety concerns. (Funded by Jiangsu Simcere Pharmaceutical; ClinicalTrials.gov number,…
View article: Discovery of (2<i>S</i>)-<i>N</i>-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
Discovery of (2<i>S</i>)-<i>N</i>-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment Open
Androgenetic alopecia (AGA) is the most prevalent form of progressive hair loss disorder in both men and women, significantly impacting their appearance and overall quality of life. Overactivation of the AR signaling pathway in dermal papi…
View article: Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir
Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir Open
The persistent pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants accentuates the great demand for developing effective therapeutic agents. Here, we repor…
View article: A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects
A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects Open
Safe and efficacious antiviral therapeutics are in urgent need for the treatment of coronavirus disease 2019. Simnotrelvir is a selective 3C-like protease inhibitor that can effectively inhibit severe acute respiratory syndrome coronavirus…
View article: SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models Open
View article: Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial
Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial Open
View article: Engineering cytokines for cancer immunotherapy: a systematic review
Engineering cytokines for cancer immunotherapy: a systematic review Open
Cytokines are pivotal mediators of cell communication in the tumor microenvironment. Multiple cytokines are involved in the host antitumor response, but the production and function of these cytokines are usually dysregulated during maligna…
View article: Efficacy and safety of Y-2 sublingual tablet for patients with acute ischaemic stroke: protocol of a phase III randomised double-blind placebo-controlled multicentre trial
Efficacy and safety of Y-2 sublingual tablet for patients with acute ischaemic stroke: protocol of a phase III randomised double-blind placebo-controlled multicentre trial Open
Background and purpose Clinical studies have demonstrated that edaravone dexborneol can improve the functional outcomes in patients with acute ischaemic stroke (AIS). The present clinical trial aimed at testing the efficacy and safety of Y…
View article: SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD) effectively shrinks tumors both in intracranial and subcutaneous ER+ breast cancer models
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD) effectively shrinks tumors both in intracranial and subcutaneous ER+ breast cancer models Open
Background: Targeted estrogen receptor degradation has been approved to effectively treat ER + breast cancers. Due to the poor bioavailability of fulvestrant, the first generation of SERD, many efforts were made to develop oral SERDs. With…
View article: Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke (TASTE-SL): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke (TASTE-SL): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Open
View article: A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents
A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents Open
Malignant ascites (MA) is caused by intraperitoneal spread of solid tumor cells and results in a poor quality of life. Chemotherapy is a common first-line treatment for patients with MA. Taxotere ® (DTX) is widely used in solid tumor thera…
View article: Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors
Targeting the Homologous Recombination Pathway in Cancer With a Novel Class of RAD51 Inhibitors Open
Targeting DNA damage response (DDR) pathway has been proposed as an approach for amplifying tumor-specific replicative lesions. RAD51 plays a central role in the DDR process, and thus represents a promising anti-tumor target. We here repor…
View article: Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs
Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs Open
Background and objective Experimental autoimmune encephalomyelitis (EAE) is the most commonly used model for studying autoimmune-mediated myelin degradation in multiple sclerosis (MS). Here, we evaluated the pharmacologic responses of seve…
View article: An Antiangiogenic Agent Associated with Multi-Targets Exhibits Synergistic Antitumor Effects in Combination with Immunotherapeutics
An Antiangiogenic Agent Associated with Multi-Targets Exhibits Synergistic Antitumor Effects in Combination with Immunotherapeutics Open
Recently, an increasing number of studies have focused on the combination of antiangiogenic agents and Immune Checkpoint Inhibitors (ICIs) in preclinical and clinical settings.In this commentary, we discuss the combination of recombinant h…
View article: Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment Open
Background Signaling through VEGF/VEGFR induces cancer angiogenesis and affects immune cells. An increasing number of studies have recently focused on combining anti-VEGF/VEGFR agents and immune checkpoint inhibitors (ICIs) to treat cancer…
View article: Antiangiogenic Antibody BD0801 Combined With Immune Checkpoint Inhibitors Achieves Synergistic Antitumor Activity and Affects the Tumor Microenvironment
Antiangiogenic Antibody BD0801 Combined With Immune Checkpoint Inhibitors Achieves Synergistic Antitumor Activity and Affects the Tumor Microenvironment Open
The authors have requested that this preprint be removed from Research Square.
View article: Heterogeneity of Neoantigen Landscape Between Primary Lesions and Their Matched Metastases in Lung Cancer
Heterogeneity of Neoantigen Landscape Between Primary Lesions and Their Matched Metastases in Lung Cancer Open
View article: Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model
Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model Open
Blockade of the complement cascade at the C5a/C5a receptor (C5aR)-axis is believed to be an attractive treatment avenue in rheumatoid arthritis (RA). However, the effects of such interventions during the early phases of arthritis remain to…